SCHEMBL7616082

SCHEMBL7616082

CCn1nccc1NC=C1C(=O)Nc2cccnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.43
KDR P35968 3/20 0.43
KMT2A Q03164 3/20 0.43
NTRK1 P04629 2/20 0.43
NTRK3 Q16288 2/20 0.43
NTRK2 Q16620 2/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
CDK5 Q00535 2/20 0.43
HDAC6 Q9UBN7 1/20 0.43
AURKA O14965 1/20 0.43
ROCK2 O75116 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
CHEK2 O96017 1/20 0.43
INSR P06213 1/20 0.43
LCK P06239 1/20 0.43
CDK1 P06493 1/20 0.43
LYN P07948 1/20 0.43
RET P07949 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7616079 1.00 GSK3B (0.43) GSK3BKDRKMT2ANTRK1NTRK3
SCHEMBL4862659 0.84 EGFR (0.46) GSK3BKDRKMT2AMEN1MAPT
SCHEMBL4862653 0.84 EGFR (0.46) GSK3BKDRKMT2AMEN1MAPT
SCHEMBL7605175 0.82 MAPT (0.44) GSK3BNTRK1MAPTIGF1RALDH1A1
SCHEMBL7605173 0.82 MAPT (0.44) GSK3BNTRK1MAPTIGF1RALDH1A1
SCHEMBL5434452 0.75 MAOA (0.43) GSK3BKDRKMT2ANTRK1NTRK3
SCHEMBL5434450 0.75 MAOA (0.43) GSK3BKDRKMT2ANTRK1NTRK3
SCHEMBL7611215 0.73 MAPT (0.45) GSK3BKDRKMT2ANTRK1NTRK3
SCHEMBL7611213 0.73 MAPT (0.45) GSK3BKDRKMT2ANTRK1NTRK3
SCHEMBL5424708 0.72 RET (0.41) GSK3BKDRKMT2ANTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX GSK3B 256/4885KDR 1225/4885KMT2A 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.